
Beijing Airdoc Technology Co., Ltd.
2251.HKHKSEHealthcareMedical - Diagnostics & Research
最新数据
HK$9.57
−HK$0.83 · -7.98%
2251.HK公司概览
历史价格可能经过调整并有所延迟。
公司概况
公司网站Beijing Airdoc Technology Co., Ltd. provides artificial intelligence (AI) empowered retina-based early detection, diagnosis, and health risk assessment solutions in Mainland China and internationally. The company offers a software as a medical device (SaMD) product, Airdoc-AIFUNDUS, which is an AI-assisted diagnosis of retinal detection product that is available in three versions comprising version 1.0 for the diagnosis of diabetic retinopathy, version 2.0 that address various fundus diseases, and version 3.0 for the diagnosis of pathological myopia and retinal detachment. It also provides the AI-FUNDUSCAMERA-P, a portable automatic and self-service fundus camera that can complete the retinal image capture without an operator; AI-FUNDUSCAMERA-D, a fully automatic and self-service desktop fundus camera; and AI-FUNDUSCAMERA-M, a multimodal health scanner that integrates biosensors that supports a number of health detection functions. In addition, the company offers health risk assessment solutions to detect risk indicators, such as retinal abnormalities and vascular diseases, vitreous abnormalities, retinal tumors, optic nerve pathologies, macular diseases, congenital anomalies of the retina, cardiovascular disease, and anemia. In addition, it develops SaMD products for glaucoma and cataracts detection; an AI-driven integrated myopia intervention solutions, including the PBM LED myopia therapy device; and an AI-based visual training product for the treatment of strabismus and amblyopia. The company was formerly known as Beijing Tulip Partner Technology Co., Ltd. and changed its name to Beijing Airdoc Technology Co., Ltd. in December 2020. Beijing Airdoc Technology Co., Ltd. was incorporated in 2015 and is headquartered in Beijing, the People’s Republic of China.
- 行业
- Medical - Diagnostics & Research
- 部门
- Healthcare
- 总部
- CN
- 首席执行官
- Da Lei Zhang
- 上市以来
- 2021年11月5日
- 雇员
- 181
市场位置
52周区间
当前HK$9.57,
- 开盘价
- HK$9.57
- 前收盘价
- HK$10.40
- 成交量
- 100
- 0× 平均值
- 平均成交量
- 4.52万
- 日均成交量
- 市值
- 9.67亿 HKD
- 贝塔
- 0.8
- 市场参考 1
- 50天平均值
- HK$10.3792
- 低于平均水平-7.80%
- 200天平均值
- HK$11.3465
- 低于平均水平-15.66%
财务数据
财务快照
最近十二个月估值与收益率
- 企业价值
- 4.95亿 CNY
- 市盈率(TTM)
- -34.72×
- 市净率(TTM)
- 0.69×
- 市销率(TTM)
- 4.79×
- EV/EBITDA
- -61.9×
- 盈利收益率
- -2.38%
- 自由现金流收益率
- -2.01%
- 股息率
- 0.00%
盈利能力和效率
- 毛利率
- 73.53%
- 营业利润率
- -20.99%
- 净利润率
- -14.41%
- 净资产收益率
- -2.03%
- 资产收益率
- -1.91%
- 投入资本回报率
- -2.55%
财务健康
- 负债权益比
- 0.02×
- 流动比率
- 10.53×
- 奥特曼 Z 分数
- 5.11
- 皮奥特罗斯基 F 分数
- 4 共 9 个
财务报表
利润率趋势
盈利能力占已公布营收的百分比。
损益趋势
营收
营业利润
净利润
| 项目(CNY) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1.73亿 CNY | 1.56亿 CNY | 2.04亿 CNY | 1.14亿 CNY | 1.15亿 CNY |
| 销货成本 | 4593.6万 CNY | 6969.1万 CNY | 7883.1万 CNY | 5780.5万 CNY | 4494万 CNY |
| 毛利 | 1.27亿 CNY | 8667.6万 CNY | 1.25亿 CNY | 5585.2万 CNY | 7024.1万 CNY |
| 研究与开发 | 5809.9万 CNY | 1.02亿 CNY | 1.12亿 CNY | 1.26亿 CNY | 6426.5万 CNY |
| 销售、一般及管理费用 | 1.06亿 CNY | 1.87亿 CNY | 2亿 CNY | 1.8亿 CNY | 1.5亿 CNY |
| 营业费用 | 1.64亿 CNY | 3.28亿 CNY | 3.11亿 CNY | 2.99亿 CNY | 2.11亿 CNY |
| 利息收入 | 1460.01万 CNY | 1523.5万 CNY | 1302.4万 CNY | 914.2万 CNY | 202.3万 CNY |
| 利息支出 | 33.61万 CNY | 22.9万 CNY | 54.5万 CNY | 43.9万 CNY | 29.8万 CNY |
| 折旧和摊销 | 2023.9万 CNY | 2347.7万 CNY | 3195.2万 CNY | 2266.5万 CNY | 1549.8万 CNY |
| 营业利润 | −3637.4万 CNY | −2.02亿 CNY | −1.86亿 CNY | −2.41亿 CNY | −1.42亿 CNY |
| 净利润 | −2497.5万 CNY | −2.55亿 CNY | −1.33亿 CNY | −1.8亿 CNY | −1.43亿 CNY |
公司数据更新于 2026年8月24日。
财报历史与展望
- 最新每股收益结果
- -0.24
EPS:实际值与预期值
近期已公布业绩
营收:实际值与预期值
近期已公布业绩
2251.HK同业公司
继续GoAI的研究
在 GoAI 中研究2251.HKresearch.disclaimer





